Article
Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results.
Acta neuropathologica communications - 2 Nov 2023
McCord Matthew, Jamshidi Pouya, Thirunavu Vineeth, Santana-Santos Lucas, Vormittag-Nocito Erica, Dittman David, Parker Stephanie, Baczkowski Joseph, Jennings Lawrence, Walshon Jordain, McCortney Kathleen, Galbraith Kristyn, Zhang Hui, Lukas Rimas V, Stupp Roger, Dixit Karan, Kumthekar Priya, Heimberger Amy B, Snuderl Matija, Horbinski Craig
Abstract excerpt
MGMT promoter methylation testing is required for prognosis and predicting temozolomide response in gliomas. Accurate results depend on sufficient tumor cellularity, but histologic estimates of cellularity are subjective. We sought to determine whether driver mutation variant allelic frequency (VAF) could serve as a more objective metric for cellularity and identify possible false-negative MGMT samples. Among 691...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.